Grant for R&D of drugs for tropical diseases

Image
Press Trust of India New Delhi
Last Updated : Jan 19 2013 | 10:33 PM IST

"The approval is for R&D projects involving clinical trials (phase I, II and III) to develop new drugs for neglected diseases of tropical regions," Minister of State, Prime Minister's Office Prithvi Raj Chavan told reporters after a meeting of the Cabinet Committee on Economic Affairs.     

He said an amount of Rs 45 crore has been earmarked during the 11th five year plan to help the pharma industry and the amount could be increased as the programme develops.     

"It would help in developing new drugs for the neglected diseases such a tuberculosis, malaria, kala-azar, filariasis, which are still a big threat in the Indian sub-continent," Chauhan said.      

The R&D programme is being conducted under the Drugs and Pharmaceutical Research Programme of Department of Science and Technology, he added.      

The department has been implementing the Drugs and Pharmaceuticals Research Programme (DPRP) since 1994-95 as a plan programme to support the pharma industry, institutional collaborative R&D projects and infrastructure.      

In 2004-05, the programme started extending soft loans to pharma industry to the tune of 70 per cent of the total cost at an interest rate of 3 per cent with a 10 year repayment period beginning from the end of the project duration.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jun 26 2008 | 3:53 PM IST

Next Story